Published online Jun 27, 2024. doi: 10.4240/wjgs.v16.i6.1918
Revised: March 20, 2024
Accepted: April 17, 2024
Published online: June 27, 2024
Processing time: 153 Days and 0.1 Hours
Myopericytoma is a benign tumor that typically occurs within subcutaneous tissue and most often involves the distal extremities, followed by the proximal extremities, neck, thoracic vertebrae and oral cavity. Complete resection is often curative. Malignant myopericytoma is extremely rare and has a poor prognosis. Here, we report for the first time a case of malignant myopericytoma originating from the colon.
A 69-year-old male was admitted to our hospital with right upper quadrant pain for five days. Imaging suggested a liver mass with hemorrhage. A malignant hepatic tumor was the initial diagnosis. Surgical resection was performed after a complete preoperative work up. Initial postoperative pathology suggested that the mass was a malignant myoblastoma unrelated to the liver. Four months after the first surgery, an enhanced computed tomography (CT) scan revealed a recurrence of the tumor. The diagnosis of malignant myopericytoma derived from the colon was confirmed on histopathological examination of the specimen from the second surgery. The patient did not return to the hospital regularly for surveillance. The first postoperative abdominal CT examination six months after the second surgery demonstrated multiple liver metastases. Survival time between the diagnosis of the tumor to death was approximately one year.
Malignant myopericytoma is a rare cancer. Preoperative diagnosis may be difficult. Due to a lack of treatment options, prognosis is poor.
Core Tip: The incidence of malignant myopericytoma is very low and prognosis is poor. Presently, there is no ideal intervention. In this case, the patient was initially admitted to hospital with pain secondary to a hemorrhage into a liver tumor. After two surgeries, the patient was definitively diagnosed with a malignant myopericytoma originating in the colon. Due to the lack of comprehensive antitumor therapy and poor patient compliance, the tumor progressed rapidly. The patient’s survival was only one year. In view of the lack of diagnostic and treatment guidelines, future clinical and basic science research on myopericytomas is warranted and can hopefully improve prognosis.